Antibody Discovery
GENEWIZ Precision Antibody Discovery service rapidly identifies and expresses antibody sequences with a broad affinity range for your target and the most promising biophysical profiles for commercialization. Utilizing next generation sequencing (NGS) of your in vivo samples (i.e., B cells, PBMCs) or in vitro libraries (i.e., phage display) and the power of machine learning with our novel bioinformatic platform, AbXtract™, powered by OpenEye and developed by Specifica, this end-to-end workflow enables high-throughput screening of your library to generate 5 – 50x more antibody leads than traditional low-throughput approaches. This results in more functionally diverse leads, even including clonotypes and rare clones, improving antibody program success.
ANTIBODY DISCOVERY SERVICE
Selecting the right antibody leads with favorable development characteristics the first time around is essential for the success of your antibody program. Combining NGS, machine learning bioinformatics, and recombinant antibody production into a singular workflow, GENEWIZ Precision Antibody Discovery empowers you to rapidly and efficiently discover candidates that you would otherwise miss with traditional screening technologies and processes.
Uncover more leads: Increase the number of clonotype leads by 5–10x compared to random colony screening and produce a set of recombinant antibodies ready for experimentation
Achieve greater library diversity: Leveraging NGS, explore the complete antibody repertoire, including rare clones, which are typically missed using low-throughput methods
Decrease sequence liabilities: NGS & computational processing help to reduce sequence liabilities and improve efficiency of downstream therapeutic development, resulting in prioritized leads based on favored developability and biophysical profiles
Discover antibodies faster: Computational processing of NGS datasets coupled with recombinant production provides a faster and more efficient screening process and production of high affinity antibody leads
ANTIBODY DISCOVERY WORKFLOW
BENEFITS OF ANTIBODY DISCOVERY USING ABXTRACT
-
1. Annotation
Annotate CDRs and framework regions of interest (ROI) -
2. Abundance / Enrichment
Enrichment based on your ROI -
3. Clustering
Maximize sequence diversity by clustering based on ROI -
4. Prioritization
Quantify sequence-based biophysical liabilities and prioritize favorable leads providing immediate gene synthesis-ready output
DELIVERABLES
Standard Deliverables
• NGS FASTQ files
• AbXtract report
• Expressed antibodies (mL to L expression scales available)
• Antibody QC report including SDS-PAGE analysis
NGS PLATFORMS
Azenta Life Sciences is a service provider of cutting-edge NGS platforms. For information on our NGS platforms, as well as recommended configurations of your projects, please visit the NGS Platforms page. Azenta does not guarantee data output or quality for sequencing-only projects.
